<rss version="2.0">
<channel>
<title>MindBranch: Biotechnology</title>
<description>Biotechnology market research products provide analysis of the latest trends, developments and market data for this industry.  Research information will help you make informed business decisions.</description>
<link>http://www.mindbranch.com/catalog/find.jsp?cat=bt</link>
<item>
<title>Biotechnology (Pharmaceuticals) Report</title>
<link>http://www.mindbranch.com/products/R3468-11441.html</link>
<description> <![CDATA[The Global Biotechnology Report Plimsoll Publishing Ltd.  Do you know.... The top 7 best trading partners in the industry? Which company has the highest sales growth? Which companies have the highest levels of debt?  This report is an in-depth financial evaluation of the Global Biotechnology Industry. Using the unique Plimsoll method of analysis, each of the top 500 Biotechnology Companies is individually assessed and ranked against each other and compared to industry averages. Using the most up-to-date financial information available, the two-page analysis provides detailed financial analysis for each organisation, including details of;    Sales growth    Trading stability   Profitability    Employee performance   Level of debt   Gearing ratio&rsquo;s   Creditor Exposure   Performance ratio&rsquo;s   Overall financial rating  Results are shown in graphical, numeric and narrative forms, and all individual analysis are measured in both the company&rsquo;s own currency, and USD ($) for ease of use. These individual analyses highlight a company&rsquo;s success just as easily as it can emphasise ]]></description>
<pubDate>Sun, 01 Nov 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Freedonia Focus on Biologicals</title>
<link>http://www.mindbranch.com/products/R761-1052.html</link>
<description> <![CDATA[This report discusses US biologicals demand  for the years 2003 and 2008, with forecasts for 2013.  Topics covered include market size, product and market segmentation, technological and product development, regulatory considerations, market environment, product and market forecasts, industry composition and leading participants.  Product segments include recombinant proteins, monoclonal antibodies (Mabs), vaccines, blood and blood derivatives, and other biologicals;  market segments cover pharmacy, ambulatory health care, hospital, other health care markets, and other markets.  This 20 page report also includes a highlights summary and a resources ]]></description>
<pubDate>Sat, 31 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Crop Protection China Market Opportunities and Challenges</title>
<link>http://www.mindbranch.com/products/R3539-252.html</link>
<description> <![CDATA[China is a traditional agricultural country, with a total area of 5,000 billion square meters stricken by plant diseases and insect pests each year. With only 7% of the world&rsquo;s arable land, China has fed 22% of the world&rsquo;s population, which is a great marvel in history. How do Chinese people achieve this? One answer is making good use of crop protection.   
China is a traditional agricultural country, with a total area of 5,000 billion square meters stricken by plant diseases and insect pests each year. With only 7% of the world&rsquo;s arable land, China has fed 22% of the world&rsquo;s population, which is a great marvel in history. How do Chinese people achieve this? One answer is making good use of crop protection. 
  
Crop protection is widely applied across the world and plays important roles in guaranteeing the safety of agricultural production and the quality of ]]></description>
<pubDate>Fri, 30 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Future of Green Biotechnology in China</title>
<link>http://www.mindbranch.com/products/R3539-254.html</link>
<description> <![CDATA[This report is the unique and latest one available in the world to provide good understanding about Green Biotechnology (GB) in China and to find out business opportunities in this field. The first edition of this report is finished soon in October 2009. 
  
Green biotechnology (GB) is mainly based on genetically modified technology and fermentation technology. Over the last thirty years, China&rsquo;s GB industry has been developing stably. Chinese scientists have applied biotechnology techniques to develop many novel crop varieties that are suited to local farming conditions and can cope with challenges. More and more products in agriculture have adopted biotechnology, and production scale has been enlarged. Increasing use of green biotechnology in agricultural production can bring a lot of benefits.
  
Driven by its substantial benefits for people, environment and economy, China&rsquo;s GB industry has witnessed fast development and has played an increasingly important role in Chinese ]]></description>
<pubDate>Mon, 19 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Biotechnology in Australia - Industry Risk Rating Report</title>
<link>http://www.mindbranch.com/products/R538-30490.html</link>
<description> <![CDATA[  Industry Risk Ratings Synopsis   This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Biotechnology in Australia industry. Industry Risk is assumed to be 'the difficulty, or otherwise, of the business operating environment'.  The report looks at the operational risk associated with this industry. Three types of risk are recognized in our analysis. These are: risk arising from within the industry itself (structural risk), risks arising from the expected future performance of the industry (growth risk) and risk arising from forces external to the industry (external sensitivity risk).  This approach is new in that it analyses non-financial information surrounding each industry. Industries are scored on a 9-point scale, where 1 represents the lowest risk and 9 the highest. The Industry Risk score measures expected Industry Risk over the coming 12-18 months.   Industry Definition   The Organisation for Economic Co-operation and Development (OECD) definition of biotechnology states that it is the application of ]]></description>
<pubDate>Sat, 17 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Scientific Research in Australia - Industry Risk Rating Report</title>
<link>http://www.mindbranch.com/products/R538-30395.html</link>
<description> <![CDATA[  Industry Risk Ratings Synopsis   This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Scientific Research in Australia industry. Industry Risk is assumed to be 'the difficulty, or otherwise, of the business operating environment'.  The report looks at the operational risk associated with this industry. Three types of risk are recognized in our analysis. These are: risk arising from within the industry itself (structural risk), risks arising from the expected future performance of the industry (growth risk) and risk arising from forces external to the industry (external sensitivity risk).  This approach is new in that it analyses non-financial information surrounding each industry. Industries are scored on a 9-point scale, where 1 represents the lowest risk and 9 the highest. The Industry Risk score measures expected Industry Risk over the coming 12-18 months.   Industry Definition   Companies in this industry undertake research in the agricultural, biological, physical or social sciences. The majority of ]]></description>
<pubDate>Sat, 17 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Biotechnology in the US - Industry Risk Rating Report</title>
<link>http://www.mindbranch.com/products/R538-31203.html</link>
<description> <![CDATA[  Industry Risk Ratings Synopsis   This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Biotechnology in the US industry. Industry Risk is assumed to be 'the difficulty, or otherwise, of the business operating environment'.  The report looks at the operational risk associated with this industry. Three types of risk are recognized in our analysis. These are: risk arising from within the industry itself (structural risk), risks arising from the expected future performance of the industry (growth risk) and risk arising from forces external to the industry (external sensitivity risk).  This approach is new in that it analyses non-financial information surrounding each industry. Industries are scored on a 9-point scale, where 1 represents the lowest risk and 9 the highest. The Industry Risk score measures expected Industry Risk over the coming 12-18 months.   Industry Definition   Biotechnology is the application of science and technology to living organisms as well as parts, products and ]]></description>
<pubDate>Sat, 17 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Plunkett's Health Care Technologies Overview 2010 (Summary)</title>
<link>http://www.mindbranch.com/products/R207-602.html</link>
<description> <![CDATA[This summary contains the complete technologies section excerpted from the highly-acclaimed Plunkett's Health Care Industry Almanac. This report will be your ready-reference guide to new and developing health care technologies. Technology topics range from stem cells, to new drug delivery systems, to gene therapies. The report includes several statistical tables. You'll find the information you need in this carefully-researched report.
]]></description>
<pubDate>Fri, 16 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Biotechnology: Global Industry Guide</title>
<link>http://www.mindbranch.com/products/R313-56811.html</link>
<description> <![CDATA[Datamonitor's Biotechnology: Global Industry Guide is an essential resource for top-level data and analysis covering the Biotechnology industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.   Scope of the Report       Contains an executive summary and data on value, volume and segmentation    Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies   Incorporates in-depth five forces competitive environment analysis and scorecards    Covers the Global, European and Asia-Pacific markets as well as individual chapters on 5 major markets (France, Germany, Japan, the UK and the US).    Includes a five-year forecast of the industry   Highlights   The global biotechnology market grew by 8.8% in 2008 to reach a value of $216.3 billion.  In 2013, the global biotechnology market ]]></description>
<pubDate>Wed, 14 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>The Human Genome Sequencing Center at Baylor College of Medicine Relies on Quantum's StorNext Software for Data Management</title>
<link>http://www.mindbranch.com/products/R104-40214.html</link>
<description> <![CDATA[ This IDC Buyer Case Study examines how one research institution utilizes Quantum's StorNext data management software to support its growing storage ]]></description>
<pubDate>Thu, 08 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Imclone Systems Inc.</title>
<link>http://www.mindbranch.com/products/R406-16444.html</link>
<description> <![CDATA[ImClone Systems Incorporated is a biopharmaceutical company dedicated to developing breakthrough biologic medicines in the area of oncology. The Company has utilized the many advances made in the fields of molecular biology, oncology, genomics and antibody engineering to build a novel pipeline of product candidates designed to address specific genetic mechanisms involved in cancer growth and ]]></description>
<pubDate>Thu, 01 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Covance Inc.</title>
<link>http://www.mindbranch.com/products/R406-16599.html</link>
<description> <![CDATA[Covance develops and carries out preclinical and clinical trials of potential commercial drugs. Services include toxicology studies, biostatistical analysis, clinical data management, and study design and monitoring. Covance will also assist a company in moving a drug through the regulatory approval process. Among the company`s customers are pharmaceutical, biotech, and medical device firms; it also offers laboratory testing services to companies in the chemical, agrochemical, and food ]]></description>
<pubDate>Thu, 01 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>EMD Serono, Inc</title>
<link>http://www.mindbranch.com/products/R406-16684.html</link>
<description> <![CDATA[Serono is a global biotechnology leader with over 4,750 employees and worldwide revenues of USD 2,586.4 million in the year 2005. We have eight biotechnology products on the market and currently more than 25 ongoing preclinical and clinical development ]]></description>
<pubDate>Thu, 01 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Parexel International Corporation</title>
<link>http://www.mindbranch.com/products/R406-16685.html</link>
<description> <![CDATA[PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development ]]></description>
<pubDate>Thu, 01 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Abraxis BioScience, Inc.</title>
<link>http://www.mindbranch.com/products/R406-17431.html</link>
<description> <![CDATA[Abraxis BioScience is an integrated, global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The   company develops, manufactures, and markets one of the broadest portfolios of injectable products and innovates revolutionary core technology such as its nab? technology platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening ]]></description>
<pubDate>Thu, 01 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Charles River Laboratories International Inc.</title>
<link>http://www.mindbranch.com/products/R406-17564.html</link>
<description> <![CDATA[Accelerating Drug Development. Exactly. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. The Company`s more than 8,500 employees worldwide are focused on providing clients with exactly what they need to improve and expedite the discovery, development through first-in-human evaluation, and safe manufacture of new therapies for the patients who need ]]></description>
<pubDate>Thu, 01 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Advances in the Use of Biomarkers in Biochip and Microarray Testing: Innovative technologies, growth opportunities and the future market outlook</title>
<link>http://www.mindbranch.com/products/R162-1002.html</link>
<description> <![CDATA[Microarrays and biochips are small devices capable of detecting and measuring large numbers of biomarkers simultaneously. Although microarrays have been in research use for over a decade it is only recently that they have moved towards meeting the requirements of the clinical and regulatory communities with the first DNA microarray test being approved by the US FDA in 2007. Further development of microarrays heralds the introduction of faster diagnosis times and will further enable personalized medicine. This report covers future developments in key segments of the microarray market including DNA, protein, tissue and cell microarrays and lab-on-a-chip technologies, providing market forecasts to 2013. In addition the report gives insights into the developmental programs of 45 leading players in this market.
]]></description>
<pubDate>Thu, 01 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Affymetrix, Inc.</title>
<link>http://www.mindbranch.com/products/R406-17747.html</link>
<description> <![CDATA[Affymetrix scientists invented the world`s first microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world`s top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,300 systems have been shipped around the world and more than 3,000 peer-reviewed papers have been published using the technology. Affymetrix` patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyze the relationship between genetics and health. Headquartered in Santa Clara, Calif., Affymetrix has subsidiaries in Europe and Asia in addition to manufacturing facilities in Sacramento, Calif. and Bedford, ]]></description>
<pubDate>Thu, 01 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Cepheid</title>
<link>http://www.mindbranch.com/products/R406-17904.html</link>
<description> <![CDATA[Cepheid based in Sunnyvale, Calif., is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical, industrial and biothreat markets. The company`s systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Through its broad molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat ]]></description>
<pubDate>Thu, 01 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Illumina Inc.</title>
<link>http://www.mindbranch.com/products/R406-17945.html</link>
<description> <![CDATA[Illumina is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the large-scale analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual ]]></description>
<pubDate>Thu, 01 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Celgene Corporation</title>
<link>http://www.mindbranch.com/products/R406-18038.html</link>
<description> <![CDATA[Celgene is a pharmaceutical company encompassing research, development, manufacturing, and sales and marketing. At Celgene, their mission is to employ their strong research capabilities and expertise toward the discovery, development and commercialization of small molecules for cancer and immunological ]]></description>
<pubDate>Thu, 01 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Exelixis Inc.</title>
<link>http://www.mindbranch.com/products/R406-18043.html</link>
<description> <![CDATA[Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis` broad product pipeline includes investigational compounds in Phase II and Phase I clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and ]]></description>
<pubDate>Thu, 01 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Genzyme Corporation</title>
<link>http://www.mindbranch.com/products/R406-18045.html</link>
<description> <![CDATA[One of the world`s leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.     With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company`s products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme`s commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, cardiovascular disease, ]]></description>
<pubDate>Thu, 01 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Geron Corporation</title>
<link>http://www.mindbranch.com/products/R406-18046.html</link>
<description> <![CDATA[Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical ]]></description>
<pubDate>Thu, 01 Oct 2009 00:00:00 EST</pubDate>
</item>
<item>
<title>Gilead Sciences Inc.</title>
<link>http://www.mindbranch.com/products/R406-18047.html</link>
<description> <![CDATA[Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company`s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and ]]></description>
<pubDate>Thu, 01 Oct 2009 00:00:00 EST</pubDate>
</item>
</channel>
</rss>
